Keywords: update, viropharma, discontinues, ph, iii, maribavir, trial

UPDATE: ViroPharma discontinues Ph III maribavir trial, shares fall 5.3%

Article | 23 February 2009

Print This

Shares in USA-based ViroPharma fell 5.3% to $6.23 on February 13, after the firm cancelled a Phase III trial evaluating maribavir to prevent ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in